Volume 18 Supplement 1

Proceedings of the International Gap Junction Conference 2015: second issue

Open Access

Pannexin channel and connexin hemichannel expression in vascular function and inflammation

  • Daniela Begandt1,
  • Miranda E Good1,
  • Alex S. Keller1,
  • Leon J. DeLalio1,
  • Carol Rowley1,
  • Brant E. Isakson1, 2 and
  • Xavier F. Figueroa3Email author
Contributed equally
BMC Cell BiologyBMC series – open, inclusive and trusted201718(Suppl 1):2

https://doi.org/10.1186/s12860-016-0119-3

Published: 17 January 2017

Abstract

Control of blood flow distribution and tissue homeostasis depend on the tight regulation of and coordination between the microvascular network and circulating blood cells. Channels formed by connexins or pannexins that connect the intra- and extracellular compartments allow the release of paracrine signals, such as ATP and prostaglandins, and thus play a central role in achieving fine regulation and coordination of vascular function. This review focuses on vascular connexin hemichannels and pannexin channels. We review their expression pattern within the arterial and venous system with a special emphasis on how post-translational modifications by phosphorylation and S-nitrosylation of these channels modulate their function and contribute to vascular homeostasis. Furthermore, we highlight the contribution of these channels in smooth muscle cells and endothelial cells in the regulation of vasomotor tone as well as how these channels in endothelial cells regulate inflammatory responses such as during ischemic and hypoxic conditions. In addition, this review will touch on recent evidence implicating a role for these proteins in regulating red blood cell and platelet function.

Keywords

Connexins Pannexins Vasculature Inflammation Endothelium Smooth muscle

Background

The vascular system is a complex network that, according to the structure and function of the vessels, can be divided into two compartments: the arterial and venous circulations, which are connected through the capillaries. Both compartments can be subdivided into different vascular segments. In the arterial circulation, conduit arteries, resistance arteries and arterioles can be recognized, and in the venous circulation, post-capillary venules, venules and veins can be distinguished [13]. All these vascular segments are designed to perform different, but complementary functions in order to provide oxygen and nutrients to all individual cells of the organism and dispose of metabolic wastes, which can only be achieved by fine regulation and coordination of vascular function along the different segments. As blood vessels are complex structures formed by several cell types, control of vascular function depends on timely and precise communication between the different cellular components of the vessel wall, mainly smooth muscle cells (SMCs) and endothelial cells (ECs) [46]. Nevertheless, blood vessels must also work in coordination with cells that are part of the blood, such as red blood cells (RBCs) and platelets [7, 8]. Thus, the control of vascular function depends on the fine communication between diverse cell types that are not always in direct contact each other.

One important mechanism of cell-to-cell communication is mediated by the release of autocrine/paracrine signals. Nitric oxide (NO), prostaglandins and ATP are widely recognized autocrine/paracrine signals that play diverse roles in the control of vascular function, such as regulation of vasomotor tone, smooth muscle proliferation, platelet aggregation, vascular permeability and leucocyte transmigration [912]. In addition, a signaling mechanism known as endothelium-derived hyperpolarization (EDH) has also been found to play an important role in the control of vasomotor tone [4, 914]. Although the biochemical identity of this signal is still controversial, it has been consistently found that the initiation of EDH signaling depends on the hyperpolarization of ECs by the activation of Ca2+-activated K+ channels of small (SKCa) and intermediate (IKCa) conductance, which, in the vascular wall, are only expressed in the endothelium [4, 913]. Additionally to autocrine/paracrine signaling, the direct cell-to-cell communication via connexin-formed gap junction channels make an important contribution to the coordination of function between the different cell types of the vessel wall and among distinct segments of the vascular network in the microcirculation [1517]. It is interesting to note that ECs and SMCs are functionally connected by gap junctions, which led to hypothesize that the EDH signaling corresponds to direct transmission of the hyperpolarizing current generated in ECs to SMCs through a gap junction-mediated pathway [4, 13].

Remarkably, connexin (Cx) proteins do not form only gap junction channels, but also may form functional hemichannels (i.e. half of a gap junction channel) that connect the cytoplasm with the extracellular milieu. Communication of the intracellular compartment with the extracellular space through low resistance membrane channels formed by connexins (i.e. gap junctions) or the structurally related proteins termed pannexins (Panxs) has emerged as key pathways to command and regulate several paracrine signaling mechanisms involved in the control of vascular function [4, 1821]. In this review, we discuss the structure, regulation and function of gap junctions, connexin hemichannels and pannexin channels in the vasculature and briefly in the circulating anuclear cells that regulate vascular function, red blood cells (RBCs) and platelets.

Structure of Connexin and Pannexin Proteins

Connexin and pannexin proteins are thought to belong to the same superfamily as they share some physic-chemical properties, such as the charged nature of the extracellular loop and the polar residue distribution in the transmembrane helices [22]. However, it remains to be determined if they evolved from a common ancestor or if they evolved convergently. All connexins and pannexins possess a similar structure with 4 transmembrane domains, two extracellular loops, an intracellular loop, and both the amino and carboxyl termini located intracellularly [23]. Generally, either six connexins or six pannexins come together and form a channel, except for Panx2 that seems to form heptamers or octamers [24]. A connexin-based hexamer is referred to as a connexin hemichannel [25]. Two connexin hemichannels from adjacent cells are able to dock and form a gap junction channel. Pannexin oligomers form pannexin channels in the membrane, similar to connexin hemichannels; however, there is limited evidence in vertebrates for pannexin channels to dock with channels of neighboring cells to form functional pannexin-formed gap junction channels [26].

In the human genome, there are 21 known isoforms of connexins that were originally grouped into three subfamilies, α, β, and γ; however, recent analyses of the evolution of connexins have regrouped them into five subfamilies, adding δ and ζ [22]. Cx32, Cx37, Cx40, Cx43, Cx45 and Cx47 are expressed in the vascular system, where Cx37, Cx40 and Cx43 are alpha connexins, Cx45 and Cx47 are gamma connexins, and Cx32 is a beta connexin [22]. All connexin isoforms have conserved regions of the second transmembrane domain, within the amino termini, and conserved cysteine residues in the extracellular loops [22]. The cytoplasmic loop and carboxyl terminus are the least conserved regions between connexins allowing for differential regulation of each connexin isoform and thus participation in unique signaling cascades, especially when multiple isoforms are expressed within the same cell [22]. Unlike connexins, there are only three mammalian pannexin isoforms, Panx1, Panx2 and Panx3, which share conserved regions in their extracellular loops, intracellular loop, and amino and carboxyl termini [20, 22, 26]. Panx1 and Panx2 each have two splice variants while the connexins are suggested to have splicing variants of their 5’-untranslated region, which can impact the translation and function of the proteins [26, 27].

Connexin and pannexin expression in the vascular wall

Connexins and pannexins are expressed throughout the cardiovascular system. The expression levels within the vascular tree are dependent upon vessel type, localization within the vessel, and the species being examined. The expression differences between macrovessels vs. microvessels and arteries vs. veins are continuing to be examined; however, the specificity of antibodies and detection of low expression levels remain limiting steps to overcome. The majority of the data of pannexin and connexin isoforms and their unique localizations along the vascular tree comes from studies using rodent models or human primary cells. Thus, species-dependent differences also add another level of complexity to our understanding of the localization and function of these isoforms within the vascular wall. Below is a brief description of the current knowledge regarding the expression of connexins and pannexins within the vascular wall (Table 1).
Table 1

Expression pattern of connexin and pannexin isoforms in vivo along the vascular tree. EC: endothelial cells; SMC: smooth muscle cells. ‘no’ indicates that a protein has yet to be identified in those size vessels, not that the protein is necessarily absent. Expression pattern varies between vascular beds

Protein

Large Arteries

Resistance Arteries and Arterioles

Capillaries

Post-Capillary Venules and Venules

Veins

References

Endothelial Cell Expression

Cx32

only in isolated primary cell line

only in isolated primary cell line

no

no (low levels in primary human cell lines)

yes

[43]

Cx37

yes

yes

yes

downstream side of valved-veins and in some ECs of the wall of non-valved veins

downstream side of valved-veins and in some ECs of the wall of non-valved veins

[2830, 33, 3639]

Cx40

yes

yes

no

no

generally no

[28, 29, 32, 33, 36, 37, 39]

Cx43

predominately areas of non-laminar flow

yes

yes

upstream side of valved-veins and in some ECs of the wall of non-valved veins

upstream side of valved-veins and in some ECs of the wall of non-valved veins

[2830, 32, 33, 3539]

Cx45

yes

no

no

no

no

[41, 42]

Cx47

no

no

no

only subset of ECs that compose the valves

only subset of ECs that compose the valves

[38]

Panx1

yes

yes

yes

yes

no

[35, 4446]

Panx2

yes

yes

no

no

no

[44, 46]

Panx3

no

<100 μm diameter

no

no

no

[44, 45]

Smooth Muscle Cell Expression

Cx32

no

no

 

no

no

[43]

Cx37

yes

yes

 

no

yes

[30, 33, 36, 37]

Cx40

no

generally no

 

no

no

[32]

Cx43

yes

yes

 

no

yes

[28, 30, 32, 33, 3537]

Cx45

yes

yes

 

yes

no

[28, 33, 37, 42]

Cx47

no

no

 

no

no

[38]

Panx1

no

yes

 

yes

no

[4446]

Panx2

yes

yes

 

no

no

[44, 46]

Panx3

no

<100 μm diameter

 

no

no

[44, 45]

Connexin expression in the vascular wall

Cx43 is, by far, the most studied connexin. It has been well characterized and found to be expressed in the vascular SMCs of large conduit vessels, such as the aorta, in numerous species [28, 29]. The SMCs from mouse and human resistance arteries and veins can also express Cx43 [3033]. Isolated primary human SMCs and ECs from arteries and veins express Cx43 [3335]. In vivo, Cx43 is expressed in arterial ECs of larger arteries only in areas of non-laminar flow, such as branching points, as well as in arterioles and capillaries, such as in the brain [2931, 36, 37]. In the murine vasculature, Cx43 is expressed by ECs of non-valved veins, such as the inferior vena cava, but in valved veins, such as the saphenous vein, is expressed solely in the ECs composing valves [36, 38, 39]. Together the literature indicates that Cx43 is expressed in both SMCs and ECs of both arterial and venous vessels; however, localization and expression levels are species- and vessel-specific. Cx43 is regularly shown to be expressed in cell lines; however, this expression may be increased or induced after the cells have been cultured because they are no longer under normal flow conditions or polarized with the physiologically appropriate neighboring cells.

Cx37 and Cx40 are also found broadly across the vascular network. Cx40 is predominantly expressed in ECs; however, a weak expression of Cx40 may also be observed in SMCs such as rat brain vessels [32]. Cx40 is rarely observed in the venous vasculature, although a few studies have found expression in murine umbilical cord vein, portal vein, and in human umbilical vein ECs (HUVECs) [33, 36, 39, 40]. Cx37 expression in SMCs has been demonstrated in arteries of various diameters from various organs as well as in isolated primary human SMCs [30, 31, 33, 36, 37]. It was specifically noted that Cx37 is not found in veins from the coronary or splenic circulations, although weak expression was found in veins from other sections of the vascular tree [36, 38, 39]. However, Cx37 is strongly expressed in ECs that compose the valves in valved veins such as the saphenous vein, but similar to Cx43, it is not expressed in the surrounding non-valvular ECs of valved veins [38]. Cx40 and Cx37 are both expressed in ECs of mice and rats throughout the arterial tree as well as in isolated human ECs [28, 3034, 36, 37, 40].

Less information is available about the roles and localization of Cx32, Cx45 and Cx47. A weak signal for Cx45 has been observed in ECs from the bovine aorta [41], but Cx45 expression is predominantly in SMCs as well as in cultured HUVSMCs [28, 33, 37, 42]. Although expression of Cx32 in vivo has only been reported in ECs of large murine veins, the analysis of primary cultures of human ECs suggest that Cx32 has significantly higher expression in ECs from larger vessels, such as HUVECs and HAECs, as compared to ECs from microvessels, such as cultured human microvascular ECs (HMVECs) [43]. Cx47 has recently been found within a small subset of ECs that compose the valves in veins [38]. As the information about these connexins (Cx32, Cx45 and Cx47) is just emerging, further studies are necessary to determine their expression and functional roles within the vasculature.

Pannexin expression in the vascular wall

Pannexin channels are expressed throughout the body. The expression of these channels continues to be explored, but recent data indicate that Panx1 is almost ubiquitously expressed in murine ECs within arteries, arterioles, and venules, as well as in isolated human cells including an immortalized brain EC line, human saphenous vein ECs (HSaVECs), and HUVECs [35, 44, 45]. Panx1 expression in murine SMCs occurs only in arterioles and venules, while Panx3 is only found in arterioles <100 μm in diameter [44, 45]. Panx2 has been observed in SMCs of the pulmonary artery of mice and in the SMCs of the rat middle cerebral artery (MCA) [44, 46]. Although mRNA of all three pannexin isoforms were found in the rat MCA, only Panx1 and Panx2 proteins were found in ECs of these vessels [46]. Lastly, as with any membrane bound protein that is expressed endogenously in low levels, it is rather difficult to detect Pannexin mRNA from small vessels. False-negative detection is a rather common occurrence and thus can not be taken to mean a lack of expression. For this reason, protein detection in small vessels in particular, is the most definitive way to detect Pannexin 1; this in conjunction with a knockout animal to validate expression. Overall, mouse and human expression appear to be the most consistent and reliable expression patterns, and thus physiologically relevant set of models, whereas the rat appears to be more random in expression.

Regulation of connexin and pannexin function in the vascular wall

Regulation of connexin hemichannels and pannexin channels can occur via changes in extracellular and intracellular Ca2+, pH or cell membrane voltage or via post-translational modifications (PTMs). PTMs are covalent protein modifications that alter protein function via the addition or removal of chemical functional groups to amino acid residues on the protein. A diverse array of PTMs exists, including phosphorylation, S-nitrosylation, glycosylation and ubiquitination, among others. These PTMs have individual effects on protein function but can also act in concert with other PTMs to regulate complex physiological responses [35]. Protein modifications by phosphorylation and S-nitrosylation are central regulators of vascular function due to the large influence of nitric oxide synthase and kinase-mediated signaling pathways during vasomotor responses in both arteries and veins [47, 48]. Research on connexin hemichannels and pannexin channels reveals evidence that the activity of these channels can be regulated by phosphorylation. Understanding how phosphorylation and S-nitrosylation modulates channel function is critical for understanding how connexin hemichannels and pannexin channels contribute to vascular homeostasis [49, 50].

Phosphorylation of connexin hemichannels

In the blood vessel wall, connexin hemichannels and gap junction channels assist in coordinating vasoconstrictor and vasodilator signaling between smooth muscle and endothelial cells [51]. Overall, a large body of research has been focused on the regulation of connexin gap junctions by phosphorylation, but far less information is available on the expression and functional control of connexin hemichannels in the vasculature [52]. Recently, a number of reports have observed that phosphorylation events on connexin hemichannels can alter channel permeability in cell culture [53]. However, there is limited information about the functional regulation of connexin hemichannels in vascular cells. Connexin hemichannels have been identified on ECs and SMCs [5456]. In these cell types, connexin hemichannel activation is linked to the release of ATP, a key signaling molecule in the blood vessel wall [9]. Although the mechanistic gating of connexin hemichannels by phosphorylation is unclear in the vasculature, studies in other cell types has suggested that hemichannels can be directly regulated by kinases. Cx43 is a well-established phospho-substrate for mitogen-activated protein (MAP) kinases, as well as protein kinase C (PKC), which have been extensively reviewed elsewhere [52, 5759]. Additionally, phosphorylation of Cx43 at amino acid serine residue S368 has been shown to reduce hemichannel opening, decrease permeability, and change ion selectivity [60, 61]. This inhibitory effect was in part confirmed in the vascular endothelium, whereby hypoxia caused a reduction in ATP release, depletion of surface Cx43, and increased phosphorylation of Cx43 S368 [54]. It is interesting to note that the inhibitory effects of hypoxia on Cx43 hemichannels from cultured astrocytes have been linked to the dephosphorylation of Cx43 hemichannels by protein phosphatases, which suggests the existence of a complex PTM network in the regulation of Cx43 hemichannels by phosphorylation [52]. Nevertheless, future studies are needed to better understand how phosphorylation of connexin hemichannels modulates vascular function, especially in vivo.

Phosphorylation of pannexin channels

In addition to the presence of connexins in the vascular wall, pannexin channels have emerged as the most dominant regulator of extracellular purinergic signaling in vascular function [6264]. A number of serine, threonine (T) and tyrosine (Y) phosphorylation sites have been predicted for pannexins based on their amino acid sequences, as well as putative recognition sites for protein kinase C (PKC), protein kinase A (PKA), and Ca2+/calmodulin-dependent protein kinase (CamKII) (Fig. 1) [6567]. However, there is still a lack of direct biochemical evidence to link specific amino acid/kinase pairs with channel function. The current landscape of Panx1 PTM by phosphorylation is dominated by the regulatory role of tyrosine phosphorylation, which plays a unique and crucial role in regulating vascular function [6870].
Fig. 1

Diagram of mouse Pannexin 1 membrane topology and post-translational modifications. Based on sequence analysis using the UniProt database, Pannexin 1 is predicted to contain four transmembrane regions. It contains four conserved extracellular cysteine residues (blue) in the extracellular loops and a confirmed N-glycosylation site (green) necessary for plasma membrane translocation. Multiple post-translational modification sites by S-Nitrosylation (pink), phosphorylation (yellow), or proteolytic caspase cleavage (gray) have been confirmed to regulate channel gating. Additional post-translational modifications were predicted and annotated using PhosphoSitePlus (orange)

Mechanistically, a link between pannexin channel gating and tyrosine kinase phosphorylation was established using Panx1-expressing J778 macrophages and targeting the C-terminal Y308 amino acid of Panx1 in rodent hippocampal brain slices [71, 72]. In the vasculature, Lohman et al. recently confirmed the role for Src family kinase (SFK)-dependent tyrosine phosphorylation at residue Y198 of Panx1 in response to TNFα-receptor stimulation in the venous endothelium [45]. In this study, stimulation of ECs with TNFα resulted in an SFK-dependent increase in phosphorylation of Panx1 at Y198, which was paralleled by an increase in SFK activity [45].

Moreover, the Panx1 Y198 site was suggested to regulate SMC contraction and vascular tone in resistance arteries [62]. Based on earlier work that characterized a novel interaction between the α1-adrenergic receptor and Panx1-mediated ATP release, Billaud et al. demonstrated that pharmacological and genetic inhibition of the Panx1 intracellular loop motif containing Y198 prevents the Panx1 channel activation, ATP release, and vasoconstriction initiated by α1-adrenoceptor stimulation [62, 63]. In addition, this study showed that SMC-specific Panx1 deletion in mice, which exhibit blunted phenylephrine (PE)-stimulated vasoconstrictor responses, could be rescued by transfecting wild type Panx1 plasmids directly into arterial SMCs, but not by plasmids containing a mutated Y198 motif. These investigations suggest that Panx1 tyrosine phosphorylation within both ECs and SMCs could play a role in the regulation of vascular function [45, 62]. However, this has yet to be proven definitely and likely is a part of a much larger PTM set of events that have yet to be uncovered.

Outside of tyrosine phosphorylation, little is known about regulation of pannexin by serine/threonine PTM. In one study using pan-phosphoserine/threonine antibodies, the electrical stimulation of skeletal muscle was shown to enhance serine/threonine phosphorylation of Panx1 [73]. The increase in phosphorylation was associated with ATP release and dye uptake, which was sensitive to channel blocking agents. In a second study, the Panx1 residue S206 has been put forth as a putative serine phosphorylation site by protein kinase G (PKG) [74]. The inhibitory effect of the nitric oxide donor sodium nitroprusside (SNP) on Panx1 channel currents was shown to act through a cGMP-PKG dependent mechanism, and mutation of the serine at residue 206 to alanine blunted the SNP-dependent inhibition of Panx1 channel currents [74]. However, this investigation did not directly demonstrate substrate specificity of PKG for S206. In the future, it will be important to determine if S206 phosphorylation by PKG negatively affects Panx1 channel activity as Panx1-mediated ATP release has been shown to control α1-adrenoceptor-induced vasoconstriction and PKG signaling pathways are known to cause cessation of vascular SMC contraction [62, 75].

S-Nitrosylation of connexin hemichannels

The addition of nitrosyl groups to cysteine (C) residues (S-nitrosylation) is another important PTM in both physiological conditions and disease [76, 77]. For connexins, there is clear evidence that NO can influence gap junction function in the vasculature, in both ECs and SMCs [7881]. However, limited evidence exists for the regulated gating of connexin hemichannels by S-nitrosylation in the blood vessel wall. The mechanisms by which NO regulates connexin hemichannel activity have primarily been investigated in the central nervous system, mainly in astrocytes [53, 82]. However, it is important to note that both astrocytes and endothelial cells express the enzyme NO synthase (NOS), and thus, similarities may exist in the PTM mechanisms that regulate connexin hemichannel activity in these two cell types.

A number of studies have linked the regulation of connexin hemichannels with the production of NO. S-Nitrosylation has been proposed to regulate Cx43 hemichannels in astrocytes and cardiomyocytes, whereby conditions of oxygen deprivation and metabolic inhibition can enhance hemichannel activity as determined by pharmacology and in vitro [83, 84]. The potential modulation of connexin hemichannels by NO-mediated events has been linked to the functional regulation of vasodilator responses. Using connexin-deficient HeLa cells, Figueroa et al. demonstrated that Cx43, Cx40, and Cx37 could be stimulated to open when treated with NO donors and additionally could act as a conduit for NO transmission [78]. The study further demonstrated that acetylcholine (ACh)-induced vasodilation and the diffusion of NO from ECs to SMCs could be blocked in mesenteric arteries by inhibiting connexin-based channels. However, future studies are needed to determine the extent to which NO-activated connexin hemichannels contribute to the regulation of vascular function.

S-Nitrosylation of pannexin channels

In addition to connexin hemichannels, evidence indicates that Panx1 channels can be regulated by S-nitrosylation. It was previously demonstrated that Panx1 channels can be activated by ischemic conditions in neurons, and that inhibition of the neuronal isoform of NOS (nNOS) during oxygen/glucose deprivation (OGD) blocks Panx1 channel activity in a NO-dependent and redox-sensitive manner [85, 86]. Direct evidence for a potential PTM site at Panx1 residue C28 was later identified in zebrafish using targeted mutagenesis experiments on cysteine residues in the intracellular and transmembrane domains of Panx1 [87]. Two later studies revealed additional residues (C40 and C346) as potential PTM sites of Panx1 [88]. Mutations of these two individual residues to serines resulted in a constitutively active channel [88]. Moreover, substitution of any of the four extracellular cysteine residues in Panx1 (C66, C84, C245, and C264) resulted in complete loss of channel function [89].

Although the previous studies did not identify Panx1 PTM by S-nitrosylation in a physiological context, they did set the stage for an investigation by Lohman et al, which demonstrated that multisite S-nitrosylation may be important for Panx1 channel gating in the vasculature [90]. The treatment of HEK and HAECs with the NO donor S-nitrosoglutathione (GSNO) induced Panx1 S-nitrosylation; however, instead of activating Panx1 as observed in neurons, NO had an inhibitory effect on channel currents and ATP release. This inhibition could be reversed by the reducing agent DTT. Furthermore, dual mutation of both C40 and C346 residues to alanine, but not either point mutation alone, was necessary to prevent GSNO-stimulated inhibition of Panx1 channel currents and ATP release. The results of this study highlight a potential negative regulatory mechanism of Panx1 channel gating by S-nitrosylation, which may balance vasoconstrictor responses produced by Panx1-mediated ATP release in SMCs of resistance arteries [62]. More recently, a similar investigation looking at the effects of NO donors on Panx1 activity in human embryonic kidney 293 (HEK) cells confirmed the observation of Lohman et al that NO donors closed Panx1 channels [74]. However, in this investigation, a PKG-dependent phosphorylation mechanism was suggested to participate in the control of channel activity, particularly by the stimulation of soluble guanylyl cyclase via NO. The mechanistic discrepancy between the two studies may be due to complex PTM regulatory signals, where multiple signaling cascades are involved in regulating pannexin channel gating as it relates to vascular function.

Connexin hemichannels and pannexin channels in the control of vasomotor tone

The regulation of blood flow distribution in the tissues relies on the well-integrated control of the microvascular resistance to blood flow by the adjustment of the diameter of resistance vessels, which depends on the level of constriction of SMCs (i.e. vasomotor tone). The contractile state of SMCs depends on the cytoplasmic Ca2+ concentration and Ca2+ sensitivity of the contractile machinery. Thereby, smooth muscle membrane potential plays a pivotal role in the regulation of vasomotor tone by temporally controlling the open probability of L-type, voltage-dependent Ca2+ channels [91, 92]. However, it is important to note that vasomotor tone is finally determined by the balance between a smooth muscle-dependent constrictor tone and an endothelium-dependent vasodilator tone [93, 94].

Connexins and pannexins in smooth muscle cell function

The SMC-constrictor tone is mainly determined by the development of myogenic tone and the activity of the sympathetic system (i.e. sympathetic tone) [95, 96]. Myogenic tone is an intrinsic property of vascular smooth muscle and corresponds to the ability of vessels to develop a basal tone in response to the intravascular blood pressure [96, 97]. Interestingly, development of myogenic tone was found to be sensitive to blockers of connexin-based gap junctions in resistance arteries [98100]. In small mesenteric resistance arteries, the myogenic response was blocked by 18α-glycyrrhetinic acid (18α-GA) and the connexin mimetic peptide 37, 43Gap27, which blocks channels formed by Cx37 or Cx43 [98]. Interestingly, the inhibition of the myogenic vasoconstriction was associated with a reduction in the pressure-induced SMC depolarization and the subsequent Ca2+ influx, which suggested that the inhibition was not related to synchronization of Ca2+ signaling, but rather to earlier signaling events such as the initiation of SMC-depolarization [98]. It is important to note that the effect of connexin mimetic peptides such as 37, 43Gap27 on connexin channels is time dependent. It has been suggested that application of these peptides for short periods of time (from 10 to 45 min) only inhibits hemichannel activity, without affecting gap junction communication, which are blocked only by much longer (>1 hr) periods of treatment [34, 101103]. The myogenic response was evaluated only after 1 hr of treatment with 37, 43Gap27, thus the contribution of gap junction channels and hemichannels must be further explored. Connexin hemichannels are mechanosensitive and, therefore, may directly form part of the vascular smooth muscle pressure-sensitive mechanism involved in the development of myogenic vasoconstriction [104]. As Cx37, but not 43, was detected by immunofluorescence in SMCs of these mesenteric arteries, the activation of Cx37 channels was proposed to be involved in the pressure-induced smooth muscle cell depolarization that triggers the initiation of the myogenic response [98]. However, the resting basal vasomotor tone of cremaster muscle arterioles of Cx37 knockout (KO) mice was not different to that observed in wild type animals, thus the participation of other Cxs, like Cx43 and/or pannexins cannot be definitively ruled out [15].

In addition to the myogenic tone, connexin hemichannels may also involved in the sympathetic nerve-triggered vasoconstriction. The sympathetic vasomotor tone is primarily mediated by norepinephrine-evoked activation of α1-adrenoceptors in SMCs [95]. It was recently reported that blockade of connexin-based channels with 18β-glycyrrhetinic acid (18β-GA) or the Cx40 blocking peptide 40Gap27 attenuates the increase in perfusion pressure induced by PE in isolated, perfused rat kidney, an effect observed within a few minutes of peptide application [105]. Furthermore, the vasoconstrictor response was not altered by the connexin-blocking peptides 37, 43Gap27 or 43Gap26, a Cx43-specific channel blocker, suggesting participation of Cx40 hemichannels in the response [105]. The inhibition of the vasoconstriction observed in the presence of 40Gap27 suggests the participation of Cx40 hemichannels in the α1-adrenoceptor-mediated control of vasomotor tone; however, the mechanism involved has not been elucidated. This also highlights the serious problem of pharmacological reliance for determination of connexin hemichannel function. This therefor requires active investigation and the impetus is certainly on the connexin hemichannel field to definitely prove these exist in vivo and without the need to use vague inhibitors (e.g., as discussed by [106]).

The vasoconstrictor response initiated by α1-adrenoceptor activation in arterioles appears to be very complex and also involves autocrine signaling mediated by ATP release through pannexin channels. Recently Billaud et al. showed that stimulation of α1-adrenoceptors leads to Panx1 channel opening, which provides the pathway for ATP release [63]. The ATP released via Panx1 channels contributes, in great part, to the α1-adrenoceptor-mediated vasoconstriction through the activation of P2Y receptors [62, 63, 107]. Interestingly, this complementary vasoconstrictor mechanism is only coupled to α1-adrenoceptor activation while the response to serotonin or endothelin-1 is not affected by typical Panx1 channel blockers such as the Panx1 mimetic peptide 10Panx and probenecid, which was confirmed in the SMC Panx1-deficient mice [62]. This observation has now been confirmed independently pharmacologically [108] and genetically [109] in mouse mesenteric arterioles (as well as humans [data not shown]) highlighting the importance of the Panx1-α1-adrenerigc interaction, especially for translational outcomes.. The activation of Panx1 channels was found to rely on the specific amino acid sequence YLK, corresponding to residues 198 to 200 of the intracellular loop of Panx1 [45, 62, 63]. This suggests that phosphorylation at Tyr198 may mediate the α1-adrenoceptor-induced Panx1 channel opening, as recently reported by Lohman et al. to occur in the activation of Panx1 channels in venous ECs in response to TNFα [45, 62, 63].

Connexins and pannexins in endothelial cell function

ECs play a central role in the regulation of vasomotor tone primarily by the production of Ca2+-dependent vasodilator signals such as NO, prostaglandins and EDH [4, 11, 12, 110]. Interestingly, NO and prostaglandins have been shown to be released through connexin hemichannels [78, 111]. It is important to note that NO may also induce the opening of hemichannels formed by the vascular connexins Cx37, Cx40 and Cx43, probably through S-nitrosylation, as demonstrated in the case of Cx43 hemichannels [78, 84]. In addition, several reports show that ECs may release ATP, a potent endothelium-dependent vasodilator, through Cx43 hemichannels and Panx1 channels [45, 54, 90, 112117]. Therefore, endothelial ATP release may be involved in the control of vasomotor tone. Consistent with this hypothesis, endothelial Panx1-dependent ATP release was recently proposed to facilitate or enhance the EDH signal activated by ACh in ECs from mouse saphenous artery through a mechanism similar to that described for the response to PE in SMCs [118]. In this case; however, the increase of extracellular ATP concentration not only triggered the activation of P2 receptors directly by ATP, but also P1 receptors indirectly by the hydrolysis of ATP to adenosine, which was proposed to contribute to the ACh-induced increase in EC [Ca2+]i [118]. Paradoxically, global deletion of Panx1 resulted in a selective reduction of the SKCa and IKCa-initiated EDH-mediated vasodilation, without affecting the NO-dependent vasodilator component of the response to ACh, although both signals (EDH and NO) are Ca2+-dependent [118]. Ablation of Panx1 in these animals did not evoke a compensatory change in the expression of Panx2 or Panx3 in the saphenous artery; thus, the mechanism by which Panx1-driven ATP release activates selectively SKCa and IKCa in ECs will have to be addressed in further investigations [118].

Connexins and pannexins in the vessel wall inflammatory response

The role of connexin-based intercellular gap junction channels in inflammation has been investigated for decades. Multiple research groups have shown that connexin-based gap junctions play an important role regulating cell-to-cell communication during inflammation-related diseases such as atherosclerosis, hypertension or diabetes (for reviews see [4, 119, 120]). However, longstanding evidence also indicates that functional connexin hemichannels are involved in inflammation. While most research of connexin hemichannels in inflammation has been focused on the brain, by investigating astrocytes, neurons, and microglia (for reviews see [121, 122]), there is in vitro evidence for both pro- and anti-inflammatory roles for connexin hemichannels in the vasculature (Table 2). Pannexin channels that are highly expressed throughout the immune and cardiovascular system [45, 123, 124] are known to be key players during inflammation, but less is known about the mechanism by which pannexins participate in the cellular inflammatory response [125]. A role has been shown for pannexins in ischaemic conditions, pro-inflammatory neurotransmitter signaling, and surgically induced injuries on ECs that are presented below (Table 2).
Table 2

Pathophysiological conditions linked to connexin hemichannel or pannexin channel regulation. EC: endothelial cells; MS: mesangial cells; n.d.: not determined

Protein

Condition

Regulation

Cell type

Tissue origin

Species

Reference

Connexin hemichannelsa

Cx43

Gram-positive bacterial cell wall component peptidoglycan-induced immune response

Opening

EC

Brain

Mouse

[128]

Cx43

Hypoxia

Opening

EC

Brain

Rat

[124]

Cx43

Hypoxia

Closure

EC

Skin

Human

[54]

Cx43

Acute ischemic stroke mimicking (absence of extracellular Ca2+)

Opening

EC

Brain

Human

[35]

Cx43

Retinal ischemia-reperfusion injury

Opening

EC

Retina

Rat

[123]

Cx43

Retinal ischemia-reperfusion injury

Opening

EC

Retina

Rat

[124]

Cx43

Bradykinin-induced inflammation

Opening

EC

Brain

Rat/bovine

[34]

Cx43

Thrombin-induced inflammatory response

Closure

EC

Cornea

Bovine

[129]

Cx43

Diabetes (high glucose/cytokines treatment)-mimicking conditions

Opening

MS

Kidney

Mouse

[132]

Cx43

Surgical implantation of medical devices

Opening

EC

n.d.

Human/rat

[130]

Pannexin channelsa

 

Panx1

Acute ischemic stroke mimicking (absence of extracellular Ca2+)

Opening

EC

Brain

Human

[35]

Panx1

Cerebral ischemia-reperfusion injury

Opening

n.d.

Brain

Rat

[125]

Panx1

Pro-inflammatory neurotransmitter CGRP release

Opening

EC

Mesentery

Rat

[37]

Panx1

M-CSF-induced HSP-70 release immune response

Opening

EC

n.d.

Human

[126]

Panx1

TNFα-induced acute inflammation

Opening

EC

Diverse

Mouse/human

[45]

Panx1

Thrombin-induced inflammation

Opening

EC

Umbilical vein

Human

[112]

Panx1

Surgical harvesting of vessel

Opening

EC

Saphenous Vein

Human

[131]

a Note that the connexin hemichannel work has been proposed almost exclusively through pharmacological extrapolation, whereas the pannexin work combines genetic and pharmacological confirmation

Role of connexin hemichannels and pannexin channels under inflammatory conditions

To date, there are only few studies carving out the distinct regulation between the activation of connexin hemichannel and/or pannexin channels. Kaneko et al. for example showed a role for both connexin hemichannels and pannexin channels in a blood–brain barrier (BBB) model system [35]. Using the human cerebral microvascular endothelial cell line hCMEC/D3, conditions mimicking acute ischemic stroke led to the opening of both Cx43 hemichannels and Panx1 channels, as observed by increased dye uptake and calcein efflux, respectively. Pharmacological inhibition with CBX or 18α-GA and knockdown with either Cx43 siRNA or Panx1 siRNA prevented the dye uptake and calcein efflux [35]. In another study, regulation of BBB ECs under inflammatory conditions was linked to connexin hemichannel opening; specifically bradykinin, a pro-inflammatory agent, evoked an increase in BBB permeability in rats through the activation of intracellular Ca2+ oscillations in ECs by a pathway sensitive to the Cx43 inhibitor Gap27, indicating the involvement of hemichannel opening and purinergic signaling in response to bradykinin [34].

Ischemic injuries resulting in inflammation also induce the opening of connexin hemichannels. In retinal ischemia-reperfusion (I/R) injury in rat, the opening of Cx43 hemichannels and gap junctional communication was shown to play a role in inflammation, vascular permeability and neuronal death [126]. In a similar study, I/R led to fragmented vessels, increased Evans Blue leakage into the retina, increased Cx43 expression, co-localization of activated astrocytes with ECs, and glial fibrillary acidic protein (GFAP) de-organization close to blood vessels resulting in retinal ganglion cell death [127]. These effects were prevented by treatment with Cx43 mimetic peptide during reperfusion, which strongly supports a Cx43 hemichannel-dependent mechanism during I/R injury [127]. Cerebral I/R injury in rats induced activation of astrocytes, microglia and further subsequent inflammatory responses. Treatment of the animals before or even after the induced ischemia with different doses of probenecid, a pannexin inhibitor, prevented I/R injury-induced inflammation and cell death by preventing increased expression of cathepsin B and calpain-1 and by increasing heat shock protein 70 (HSP70) release [128, 129]. Although these studies were done in different organs, namely retina and brain, they suggest a role of connexin hemichannels and pannexin channels in the I/R injury.

Hypoxia alone also appears to independently regulate connexin-based hemichannel opening in vitro. In rat brain microvascular endothelial R840K-05a cells, hypoxia-induced cell death could be rescued by the application of hemichannel inhibitors carbenoxolone (CBX), La3+ or Cx43 mimetic peptide [127]. Interestingly, astrocytes at penetrating vessels in the medulla oblongata release ATP via Cx26 hemichannel under hypercapnia (elevated arterial P CO2 ) to signal for breathing regulation [130]. Both conditions, low O2 levels and increased CO2 levels, signal via connexin hemichannel-mediated ATP release. However, studies also showed that in human microvascular ECs of dermal origin, induction of hypoxia for 48 h attenuated Cx43 hemichannel-mediated ATP release. In this study, Cx43 transcript, total, and surface protein levels were all reduced, and Cx43 showed higher phosphorylation at S368 (which leads to a closed state of this hemichannel) [54]. The regulation of Cx43 hemichannel activity as well as a potential role of pannexin channels in hypoxic conditions, remains to be investigated.

Exposure to pathogen-associated molecular patterns (PAMPs) causes the opening of Cx43 hemichannels in ECs of the BBB, which induces an early inflammatory process. Incubation of b.End5 cells, a murine brain endothelial cell line, with the gram-positive cell wall component peptidoglycan for 24 h induces an ATP release via PKC-dependent Cx43 hemichannel opening, resulting in increases in mRNA expression levels of Cx43, Interleukin-6 (IL-6) and Toll-like receptor 2 (TLR2). These results demonstrate the role of Cx43 hemichannels in early inflammatory response, which occurs before changing the inflammatory related gene expression [131]. Another pro-inflammatory TNFa-induced ATP release was shown to be Panx1-dependent. Lohman et al. recently identified an important mechanism of regulation of endothelial Panx1 channels in TNFα-induced inflammation ex vivo, using dissected mesenteric veins, and in vitro, using isolated human primary venous ECs [45]. Application of TNFα induced, within minutes, ATP release into the lumen of cannulated veins or into the media of cultured cells. Importantly, this effect was only seen in veins or venous ECs, but not in arteries or arterial ECs. This ATP release was Panx1 channel-mediated as shown by prevention of ATP release with pharmacological inhibitors, such as CBX or 10Panx, and with siRNA-mediated knockdown of Panx1. siRNA knockdown of Cx43, conversely, had no effect. Furthermore, cannulated veins from EC-specific Panx1-deficient mice failed to release ATP following TNFα stimulation. TNFα induced SFK-dependent phosphorylation at tyrosine Y198 in the intracellular loop of Panx1, leading to the opening of the channel. Intravital microscopy demonstrated that TNFα induced leukocyte adhesion and emigration was blunted in EC-specific Panx1-deficient mice [45]. In a similar study, thrombin induced a robust, Ca2+-dependent ATP release via Panx1 channels in HUVECs [115]. Pro-inflammatory mediators like thrombin or histamine were also reported to induce the inhibition of Cx43 hemichannel-mediated ATP release by either a rapid and transient RhoA activation or the activation of phospholipase C (PLC), depending on which G protein was expressed in the cell [132]. These results highlight Panx1 as well as Cx hemichannels as a key protein for the crosstalk between cytokine and purinergic signaling in early inflammation.

In addition to known vascular diseases, surgical implantation of medical devices can also trigger inflammatory responses that involve connexin hemichannel activity. This inflammatory response leads to thickening of the implant/muscle interface and increased numbers of infiltrating neutrophils [133]. Application of a Cx43 mimetic peptide (JM2), which binds to the microtubule binding domain of Cx43, resulted in the inhibition of Cx43 hemichannel-mediated ATP release in cultured HMVEC [133]. When applied to rats with a silicone implant, the JM2 peptide restored the matrix formation and cellularity surrounding the implants and reduced the number of infiltrated neutrophils, suggesting that blockade of Cx43 hemichannel opening and subsequent ATP release into the vasculature could reduce inflammation and improve tissue healing after implant surgery [133]. Similar to Cx43 hemichannel regulation during surgical intervention, surgical harvesting of human saphenous veins induced endothelial and/or smooth muscle injuries resulting in cellular dysfunction and intimal thickening, possibly due to ischemia in the vein following extraction. Intimal injuries during surgery led to ATP release, which evoked P2X7 receptor and/or Panx1 channel activation with subsequent P2X7 receptor downstream signaling. Pharmacological inhibition of Panx1 and P2X7R with probenecid and oxidized ATP, respectively, prevented inflammatory intimal hyperplasia and, therefore, could be a possible therapeutic target for improving successful grafting of vessels [134].

A functional role of Panx1 was also suggested in the signaling between the nervous and vascular system under pro-inflammatory conditions. Stimulation of primary arterial endothelial mesenteric cells and intact mesenteric arteries with the neurotransmitter calcitonin gene-related peptide (CGRP) leads to Panx1 channel opening as shown by ethidium uptake, which was prevented by the specific inhibition of CGRP receptors with the peptide CGRP8-37 or the blockade of Panx1 channels with probenecid. Furthermore, stimulation of perivascular sensory nerves with capsaicin led to CGRP release and downregulation of endothelial NOS (eNOS) expression, linking pro-inflammatory induced neurotransmitter release to the development of endothelial dysfunction during inflammation via decreased eNOS protein levels [37]. A possible role for connexin hemichannels was not investigated.

The development of renal and cellular alterations during diabetes in rats has been linked to increased Cx43 hemichannel opening in mesangial cells, specialized cells surrounding blood vessels in the kidney. Mouse MES-13 mesangial cells treated with high glucose and cytokines (tumor necrosis factor α (TNFα), IL-1β) for 48 h displayed an increase in cellular permeability that correlated with an enhanced uptake of ethidium bromide, suggesting an increase in connexin hemichannel opening [135]. However, pannexin channels cannot be ruled out and necessitate further pharmacological or genetic experiments. Taken together the data predominately suggest that preventing/reducing connexin hemichannel or pannexin channel opening may reduce inflammation in response to various stimuli.

Connexins and pannexins in anuclear circulating blood cells

Pannexins in RBCs

Long viewed simply as carriers of oxygen, in the past two decades red blood cells (RBCs) have received renewed attention for their potential ‘erythrocrine’ function; i.e., the ability to influence their own distribution across the vasculature by participating in signaling pathways that result in the modulation of vascular tone, thus controlling blood flow to tissues with relatively greater or lesser need of oxygenation [7, 136, 137]. Ellsworth et al. proposed in 1995 a pathway involving RBC release of ATP into the vessel lumen based on the knowledge that RBCs release ATP in response to hypoxic conditions and that ATP application results in significant increases in RBC supply rate to both arterioles and venules at the end of a capillary network [136, 138]. ATP released by RBCs is thought to bind to G protein-coupled P2Y receptors on the endothelium, initiating a signaling cascade to produce and release peripheral vasodilatory signaling molecules such as NO and prostacyclin [136]. Upstream transmission of this vasodilator response allows blood flow to be modulated to match local oxygen demand [139]. ATP is released when human RBCs are exposed to O2 tensions equivalent to 50% hemoglobin oxygen saturation [140]. Further supporting the central role of RBCs in this process, perfusion of blood vessels with RBCs was shown to be necessary to elicit vessel dilation in response to hypoxia [141]. This phenomenon is also supported by exercise data showing that changes in the levels of circulating ATP in blood plasma are proportional to changes in the oxygenation state of hemoglobin in RBCs [137].

A mechanism for ATP release was provided by the detection of functional Panx1 channels in RBCs, and by the lack of Cx43 and vesicular release of ATP in RBCs under physiological conditions (Table 3) [142, 143]. Inhibition of RBC ATP release with the pannexin inhibitors CBX, probenecid, and 10Panx later clarified that Panx1 is responsible for ATP release from human RBCs in response to hypoxia, though not for a separate mechanism of ATP release in response to activation of the prostacyclin receptor [144]. Additionally, mechanical deformation of RBCs has been found to induce ATP release via a pathway similar to that of hypoxia-induced ATP release, with impairment of RBC deformability also impairing hypoxic ATP release [140, 145]. The exact mechanism of Panx1 opening in response to hypoxia or RBC deformation remains unsolved, but a variety of data suggests that Panx1 lies downstream of the mechanosensitive G protein-coupled receptor Gi, (e.g. P2Y receptors), adenylyl cyclase, and cAMP synthesis [140, 144, 146]. However, RBCs are still able to release ATP in response to direct Gi stimulation when RBC deformation is prevented. These observations suggest that hypoxia and deformation of RBCs is linked, possibly by Gi to initiate the signaling cascade culminating in Panx1-dependent release of ATP into the vessel lumen [145]. The resulting NO that serves as a vasodilator may, in turn, inhibit ATP release in a negative feedback loop [140]. While the mechanism has not been fully explained, this negative feedback is thought to occur via NO-derived inactivation of Gi [146]. However, the recent discovery that Panx1 can be inhibited directly by NO via S-nitrosylation on amino acid residues C40 and C346 offers an alternative explanation that must be investigated [90].
Table 3

Expression pattern of connexin and pannexin isoforms in red blood cells (RBCs) and platelets. ‘no’ indicates that a protein has yet to be identified in those cells

Protein

RBCs

Platelets

References

Cx32

no

low levels

[147]

Cx37

no

yes

[146, 147]

Cx40

no

yes

[147]

Cx43

no

low levels

[147]

Panx1

yes

yes

[139, 140] / [149, 150]

Panx2

no

no

 

Panx3

no

no

 

Connexins and Pannexins in Platelets

Platelets are anuclear cells found in blood that, in the presence of endothelial damage, bind exposed collagen on the basement membrane of the vessel wall. Further, they are activated to release α-granules that contain a variety of growth and clotting factors and dense granules that contain ADP, ATP, Ca2+, serotonin, and histamine; signals that promote further platelet aggregation [147]. Certain pathologic conditions result in elevated platelet activity outside of normal hemostasis, including chronic infectious or inflammatory conditions such as atherosclerosis [147]. When an atherosclerotic plaque ruptures, platelets erroneously become activated, often leading to thrombosis and possible vessel occlusion [148]. Interrupting pathogenic platelet activation and aggregation is therefore an important strategy to prevent and combat thrombosis.

The most common connexin found on the surface of human platelets by immunohistochemistry is Cx37, with lower amounts of Cx32, Cx40, and Cx43 also reported (Table 3) [149, 150]. Platelet α-granule and dense granule secretion was significantly reduced after platelets were stimulated with collagen-related peptide (CRP-XL) in the presence of connexin inhibitors, 37,43Gap27, CBX or 18β-GA, suggesting a role for connexin hemichannels during platelet activation [150]. In addition, connexin inhibitors decreased binding of individual platelets to fibrinogen and inhibited platelet aggregation [150]. However, Cx37-deficient mouse platelets did not reveal a significant difference in α-granule and dense granule secretion compared to WT platelets when stimulated with CRP-XL, implicating a connexin other than Cx37 mediates platelet granule secretion [150]. Overall, the findings of Vaiyapuri et al. suggest that connexin hemichannel activity plays an important role in platelet activation and initiation of aggregation via fibrinogen binding.

Interestingly, 40Gap27-treated human platelets and Cx40-deficient mouse platelets both showed decreased fibrinogen binding compared to WT when platelets were stimulated with CRP-XL [151]. Inhibition or deletion of Cx40 in platelets also showed significantly decreased expression of P-selectin, a marker of α-granule secretion [151]. These studies may support a role for Cx40 hemichannels, in promoting platelet activation and aggregation. Further investigation of how Cx40 hemichannels may be activated is required.

Panx1 has also been identified on the surface of human platelets, but not Panx2 or Panx3 [152, 153]. Panx1 inhibition or deletion in platelets resulted in impaired collagen-induced aggregation, ATP release, and Ca2+ influx [152, 153]. Molica et al. reported that, in platelets, Panx1 co-immunoprecipitates with P2X1, an ATP-gated channel involved in thrombosis [152]. Inhibition of P2X1 with NF449 decreased collagen-induced platelet aggregation, which was not restored by potassium-stimulated opening of Panx1 channels [152]. Taylor et al. found that the Panx1 inhibitors probenecid and CBX, impaired collagen, thrombin, and TXA2 analogue-induced Ca2+ influx, possibly through P2X1 signaling [153, 154]. Together, these data suggest that P2X1 signaling occurs downstream of Panx1 [152154]. Platelets from patients homozygous for the Panx1-400C polymorphism, which results in a change from glutamine to histamine at residue 5 in the Panx1 amino-terminus, release elevated amounts of ATP at rest when stimulated with K+ and demonstrate increased collagen-induced platelet reactivity compared to platelets with the Panx1-400A allele coding for glutamine [152]. In addition, a higher frequency of the Panx1-400C allele was found in cardiovascular patients with hyper-reactive platelets compared to those with hypo-reactive platelets [152]. Further evaluation of connexin- and pannexin-dependent signaling in platelets may provide a new therapeutic target for cardiovascular patients.

Conclusions

Connexin hemichannels and Panx channels may play an important role in the vascular system, not only in the coordination of endothelial and smooth muscle cell signaling, but also in the control of blood cell function in normal conditions as well as during inflammation. Although several connexin and Panx isoforms are expressed in the vessel wall and blood cells, the signaling mediated by connexin hemichannels and Panx channels in the vascular system seems to rely mainly on channels formed by Cx43 and Panx1, respectively. Both Cx43 and Panx1 have several sites that can be modulated by phosphorylation and S-nitrosylation, which provides mechanisms for rapid and fine regulation of the activity of these channels and for cross talk between the interactions of different signaling pathways.

The most relevant signaling mechanism mediated by connexin hemichannels and Panx channels between the cells of the vascular system is the release of ATP. However, connexin hemichannels and Panx channels are also permeable to Ca2+, which is a key second messenger in the control of vasomotor tone by both endothelial cells and smooth muscle cells. In any case, the possible direct contribution of these channels to the regulation of intracellular Ca2+ dynamics in the cells of the vessel wall remains to be determined. In addition, although most cells of the vascular system express connexins and Panx channels, it should be noted that the function of these channels is not redundant, as can be observed, for instance, in the vasoconstriction of smooth muscle cells initiated by intravascular blood pressure (i.e. myogenic response) or α1-adrenoceptor activation. The functional specificity of these channels suggests that the manipulation of their activity may provide the opportunity to design novel pharmacological strategies for the treatment of diseases associated with the development of vascular dysfunction or inflammation.

In summary, although multiple connexin and pannexin isoforms have been found in the vasculature as well as the anuclear circulating cells, their channel regulations and functions remain a topic of intense investigation. The separation between connexin hemichannel and pannexin channel function is difficult to ascertain, however it remains vital to explore these mechanisms as there are both convergent and divergent functions throughout the vasculature to maintain homeostasis.

Declarations

Declarations

This article has been published as part of BMC Cell Biology Volume 18 Supplement 1, 2017: Proceedings of the International Gap Junction Conference 2015: second issue. The full contents of the supplement are available online at http://bmccellbiol.biomedcentral.com/articles/supplements/volume-18-supplement-1.

Funding

This work was supported by National Institutes of Health grants HL088554 (B.E.I.), HL120840 (B.E.I.), HL131399 (M.E.G), and CV Training Grant HL007284 (M.E.G.) and Grant #1150530 from Fondo Nacional de Desarrollo Científico y Tecnológico – FONDECYT (X.F.F.).

Availability of data and material

Not applicable.

Authors’ contributions

DB, MEG, ASK, LJD, CR, BEI and XFF wrote and revised the manuscript. All authors read and approved the final manuscript.

Consent for publication

Not applicable.

Ethics and approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Robert M Berne Cardiovascular Research Center, University of Virginia School of Medicine
(2)
Department of Molecular Physiology and Biophysics, University of Virginia School of Medicine
(3)
Departamento de Fisiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile

References

  1. Davis MJ, Ferrer PN, Gore RW. Vascular anatomy and hydrostatic pressure profile in the hamster cheek pouch. Am J Phys. 1986;250(2 Pt 2):H291–303.Google Scholar
  2. Lockhart CJ, Hamilton PK, Quinn CE, McVeigh GE. End-organ dysfunction and cardiovascular outcomes: the role of the microcirculation. Clin Sci (Lond). 2009;116(3):175–90.View ArticleGoogle Scholar
  3. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev. 1990;70(4):921–61.PubMedGoogle Scholar
  4. Figueroa XF, Duling BR. Gap junctions in the control of vascular function. Antioxid Redox Signal. 2009;11(2):251–66.PubMedPubMed CentralView ArticleGoogle Scholar
  5. Segal SS. Integration of blood flow control to skeletal muscle: key role of feed arteries. Acta Physiol Scand. 2000;168(4):511–8.PubMedView ArticleGoogle Scholar
  6. Segal SS. Regulation of blood flow in the microcirculation. Microcirculation. 2005;12(1):33–45.PubMedView ArticleGoogle Scholar
  7. Cortese-Krott MM, Kelm M. Endothelial nitric oxide synthase in red blood cells: key to a new erythrocrine function? Redox Biol. 2014;2:251–8.PubMedPubMed CentralView ArticleGoogle Scholar
  8. Rossaint J, Zarbock A. Platelets in leucocyte recruitment and function. Cardiovasc Res. 2015;107(3):386–95.PubMedView ArticleGoogle Scholar
  9. Lohman AW, Billaud M, Isakson BE. Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovasc Res. 2012;95(3):269–80.PubMedPubMed CentralView ArticleGoogle Scholar
  10. Moncada S. Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond Ser B Biol Sci. 2006;361(1469):735–59.View ArticleGoogle Scholar
  11. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43(2):109–42.PubMedGoogle Scholar
  12. Vanhoutte PM. COX-1 and vascular disease. Clin Pharmacol Ther. 2009;86(2):212–5.PubMedView ArticleGoogle Scholar
  13. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002;23(8):374–80.PubMedView ArticleGoogle Scholar
  14. Feletou M, Vanhoutte PM. EDHF: an update. Clin Sci (Lond). 2009;117(4):139–55.View ArticleGoogle Scholar
  15. Figueroa XF, Duling BR. Dissection of two Cx37-independent conducted vasodilator mechanisms by deletion of Cx40: electrotonic versus regenerative conduction. Am J Physiol Heart Circ Physiol. 2008;295(5):H2001–7.PubMedPubMed CentralView ArticleGoogle Scholar
  16. Figueroa XF, Isakson BE, Duling BR. Connexins: gaps in our knowledge of vascular function. Physiology (Bethesda). 2004;19:277–84.View ArticleGoogle Scholar
  17. Jobs A, Schmidt K, Schmidt VJ, Lubkemeier I, van Veen TA, Kurtz A, Willecke K, de Wit C. Defective Cx40 maintains Cx37 expression but intact Cx40 is crucial for conducted dilations irrespective of hypertension. Hypertension. 2012;60(6):1422–9.PubMedView ArticleGoogle Scholar
  18. Bruzzone R, Hormuzdi SG, Barbe MT, Herb A, Monyer H. Pannexins, a family of gap junction proteins expressed in brain. Proc Natl Acad Sci U S A. 2003;100(23):13644–9.PubMedPubMed CentralView ArticleGoogle Scholar
  19. Lohman AW, Isakson BE. Differentiating connexin hemichannels and pannexin channels in cellular ATP release. FEBS Lett. 2014;588(8):1379–88.PubMedPubMed CentralView ArticleGoogle Scholar
  20. Panchin YV. Evolution of gap junction proteins--the pannexin alternative. J Exp Biol. 2005;208(Pt 8):1415–9.PubMedView ArticleGoogle Scholar
  21. Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC. Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev. 2003;83(4):1359–400.PubMedView ArticleGoogle Scholar
  22. Abascal F, Zardoya R. Evolutionary analyses of gap junction protein families. Biochim Biophys Acta. 2013;1828(1):4–14.PubMedView ArticleGoogle Scholar
  23. Sohl G, Willecke K. Gap junctions and the connexin protein family. Cardiovasc Res. 2004;62(2):228–32.PubMedView ArticleGoogle Scholar
  24. Ambrosi C, Gassmann O, Pranskevich JN, Boassa D, Smock A, Wang J, Dahl G, Steinem C, Sosinsky GE. Pannexin1 and Pannexin2 channels show quaternary similarities to connexons and different oligomerization numbers from each other. J Biol Chem. 2010;285(32):24420–31.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol. 2003;4(4):285–94.PubMedView ArticleGoogle Scholar
  26. Shestopalov VI, Panchin Y. Pannexins and gap junction protein diversity. Cell Mol Life Sci. 2008;65(3):376–94.PubMedView ArticleGoogle Scholar
  27. Salameh A. Life cycle of connexins: regulation of connexin synthesis and degradation. Adv Cardiol. 2006;42:57–70.PubMedView ArticleGoogle Scholar
  28. Brisset AC, Isakson BE, Kwak BR. Connexins in vascular physiology and pathology. Antioxid Redox Signal. 2009;11(2):267–82.PubMedPubMed CentralView ArticleGoogle Scholar
  29. Gabriels JE, Paul DL. Connexin43 is highly localized to sites of disturbed flow in rat aortic endothelium but connexin37 and connexin40 are more uniformly distributed. Circ Res. 1998;83(6):636–43.PubMedView ArticleGoogle Scholar
  30. Matchkov VV, Rahman A, Bakker LM, Griffith TM, Nilsson H, Aalkjaer C. Analysis of effects of connexin-mimetic peptides in rat mesenteric small arteries. Am J Physiol Heart Circ Physiol. 2006;291(1):H357–67.PubMedView ArticleGoogle Scholar
  31. Wagner C. Function of connexins in the renal circulation. Kidney Int. 2008;73(5):547–55.PubMedView ArticleGoogle Scholar
  32. Little TL, Beyer EC, Duling BR. Connexin 43 and connexin 40 gap junctional proteins are present in arteriolar smooth muscle and endothelium in vivo. Am J Phys. 1995;268(2 Pt 2):H729–39.Google Scholar
  33. Pogoda K, Fuller M, Pohl U, Kameritsch P. NO, via its target Cx37, modulates calcium signal propagation selectively at myoendothelial gap junctions. Cell Commun Signal. 2014;12:33.PubMedPubMed CentralView ArticleGoogle Scholar
  34. De Bock M, Culot M, Wang N, Bol M, Decrock E, De Vuyst E, da Costa A, Dauwe I, Vinken M, Simon AM, et al. Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood-brain barrier permeability. J Cereb Blood Flow Metab. 2011;31(9):1942–57.PubMedPubMed CentralView ArticleGoogle Scholar
  35. Kaneko Y, Tachikawa M, Akaogi R, Fujimoto K, Ishibashi M, Uchida Y, Couraud PO, Ohtsuki S, Hosoya K, Terasaki T. Contribution of pannexin 1 and connexin 43 hemichannels to extracellular calcium-dependent transport dynamics in human blood-brain barrier endothelial cells. J Pharmacol Exp Ther. 2015;353(1):192–200.PubMedView ArticleGoogle Scholar
  36. Traub O, Hertlein B, Kasper M, Eckert R, Krisciukaitis A, Hulser D, Willecke K. Characterization of the gap junction protein connexin37 in murine endothelium, respiratory epithelium, and after transfection in human HeLa cells. Eur J Cell Biol. 1998;77(4):313–22.PubMedView ArticleGoogle Scholar
  37. Gaete PS, Lillo MA, Figueroa XF. Functional role of connexins and pannexins in the interaction between vascular and nervous system. J Cell Physiol. 2014;229(10):1336–45.PubMedView ArticleGoogle Scholar
  38. Munger SJ, Kanady JD, Simon AM. Absence of venous valves in mice lacking Connexin37. Dev Biol. 2013;373(2):338–48.PubMedView ArticleGoogle Scholar
  39. Chang CJ, Wu LS, Hsu LA, Chang GJ, Chen CF, Yeh HI, Ko YS. Differential endothelial gap junction expression in venous vessels exposed to different hemodynamics. J Histochem Cytochem. 2010;58(12):1083–92.PubMedPubMed CentralView ArticleGoogle Scholar
  40. Miquerol L, Thireau J, Bideaux P, Sturny R, Richard S, Kelly RG. Endothelial plasticity drives arterial remodeling within the endocardium after myocardial infarction. Circ Res. 2015;116(11):1765–71.PubMedView ArticleGoogle Scholar
  41. Begandt D, Bader A, Gerhard L, Lindner J, Dreyer L, Schlingmann B, Ngezahayo A. Dipyridamole-related enhancement of gap junction coupling in the GM-7373 aortic endothelial cells correlates with an increase in the amount of connexin 43 mRNA and protein as well as gap junction plaques. J Bioenerg Biomembr. 2013;45(4):409–19.PubMedView ArticleGoogle Scholar
  42. Kruger O, Plum A, Kim JS, Winterhager E, Maxeiner S, Hallas G, Kirchhoff S, Traub O, Lamers WH, Willecke K. Defective vascular development in connexin 45-deficient mice. Development. 2000;127(19):4179–93.PubMedGoogle Scholar
  43. Okamoto T, Akiyama M, Takeda M, Gabazza EC, Hayashi T, Suzuki K. Connexin32 is expressed in vascular endothelial cells and participates in gap-junction intercellular communication. Biochem Biophys Res Commun. 2009;382(2):264–8.PubMedView ArticleGoogle Scholar
  44. Lohman AW, Billaud M, Straub AC, Johnstone SR, Best AK, Lee M, Barr K, Penuela S, Laird DW, Isakson BE. Expression of pannexin isoforms in the systemic murine arterial network. J Vasc Res. 2012;49(5):405–16.PubMedPubMed CentralView ArticleGoogle Scholar
  45. Lohman AW, Leskov IL, Butcher JT, Johnstone SR, Stokes TA, Begandt D, DeLalio LJ, Best AK, Penuela S, Leitinger N, et al. Pannexin 1 channels regulate leukocyte emigration through the venous endothelium during acute inflammation. Nat Commun. 2015;6:7965.PubMedPubMed CentralView ArticleGoogle Scholar
  46. Burns AR, Phillips SC, Sokoya EM. Pannexin protein expression in the rat middle cerebral artery. J Vasc Res. 2012;49(2):101–10.PubMedPubMed CentralView ArticleGoogle Scholar
  47. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000;522(Pt 2):177–85.PubMedPubMed CentralView ArticleGoogle Scholar
  48. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489–509.PubMedView ArticleGoogle Scholar
  49. Johnstone SR. Going against the flow: the connexin connection in hypertension. Hypertension. 2015;65(3):502–4.PubMedView ArticleGoogle Scholar
  50. Penuela S, Harland L, Simek J, Laird DW. Pannexin channels and their links to human disease. Biochem J. 2014;461(3):371–81.PubMedView ArticleGoogle Scholar
  51. Johnstone S, Isakson B, Locke D. Biological and biophysical properties of vascular connexin channels. Int Rev Cell Mol Biol. 2009;278:69–118.PubMedPubMed CentralView ArticleGoogle Scholar
  52. Solan JL, Lampe PD. Connexin43 phosphorylation: structural changes and biological effects. Biochem J. 2009;419(2):261–72.PubMedPubMed CentralView ArticleGoogle Scholar
  53. Saez JC, Retamal MA, Basilio D, Bukauskas FF, Bennett MV. Connexin-based gap junction hemichannels: gating mechanisms. Biochim Biophys Acta. 2005;1711(2):215–24.PubMedPubMed CentralView ArticleGoogle Scholar
  54. Faigle M, Seessle J, Zug S, El Kasmi KC, Eltzschig HK. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PLoS One. 2008;3(7):e2801.PubMedPubMed CentralView ArticleGoogle Scholar
  55. Song M, Yu X, Cui X, Zhu G, Zhao G, Chen J, Huang L. Blockade of connexin 43 hemichannels reduces neointima formation after vascular injury by inhibiting proliferation and phenotypic modulation of smooth muscle cells. Exp Biol Med (Maywood). 2009;234(10):1192–200.View ArticleGoogle Scholar
  56. Toma I, Bansal E, Meer EJ, Kang JJ, Vargas SL, Peti-Peterdi J. Connexin 40 and ATP-dependent intercellular calcium wave in renal glomerular endothelial cells. Am J Physiol Regul Integr Comp Physiol. 2008;294(6):R1769–76.PubMedPubMed CentralView ArticleGoogle Scholar
  57. D'Hondt C, Iyyathurai J, Vinken M, Rogiers V, Leybaert L, Himpens B, Bultynck G. Regulation of connexin- and pannexin-based channels by post-translational modifications. Biol Cell. 2013;105(9):373–98.PubMedView ArticleGoogle Scholar
  58. Lampe PD, Lau AF. Regulation of gap junctions by phosphorylation of connexins. Arch Biochem Biophys. 2000;384(2):205–15.PubMedView ArticleGoogle Scholar
  59. Lampe PD, TenBroek EM, Burt JM, Kurata WE, Johnson RG, Lau AF. Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication. J Cell Biol. 2000;149(7):1503–12.PubMedPubMed CentralView ArticleGoogle Scholar
  60. Bao X, Lee SC, Reuss L, Altenberg GA. Change in permeant size selectivity by phosphorylation of connexin 43 gap-junctional hemichannels by PKC. Proc Natl Acad Sci U S A. 2007;104(12):4919–24.PubMedPubMed CentralView ArticleGoogle Scholar
  61. Bao X, Reuss L, Altenberg GA. Regulation of purified and reconstituted connexin 43 hemichannels by protein kinase C-mediated phosphorylation of Serine 368. J Biol Chem. 2004;279(19):20058–66.PubMedView ArticleGoogle Scholar
  62. Billaud M, Chiu YH, Lohman AW, Parpaite T, Butcher JT, Mutchler SM, DeLalio LJ, Artamonov MV, Sandilos JK, Best AK, et al. A molecular signature in the pannexin1 intracellular loop confers channel activation by the alpha1 adrenoreceptor in smooth muscle cells. Sci Signal. 2015;8(364):ra17.PubMedPubMed CentralView ArticleGoogle Scholar
  63. Billaud M, Lohman AW, Straub AC, Looft-Wilson R, Johnstone SR, Araj CA, Best AK, Chekeni FB, Ravichandran KS, Penuela S, et al. Pannexin1 regulates alpha1-adrenergic receptor- mediated vasoconstriction. Circ Res. 2011;109(1):80–5.PubMedPubMed CentralView ArticleGoogle Scholar
  64. Good ME, Begandt D, DeLalio LJ, Keller AS, Billaud M, Isakson BE. Emerging concepts regarding pannexin 1 in the vasculature. Biochem Soc Trans. 2015;43(3):495–501.PubMedPubMed CentralView ArticleGoogle Scholar
  65. Penuela S, Bhalla R, Gong XQ, Cowan KN, Celetti SJ, Cowan BJ, Bai D, Shao Q, Laird DW. Pannexin 1 and pannexin 3 are glycoproteins that exhibit many distinct characteristics from the connexin family of gap junction proteins. J Cell Sci. 2007;120(Pt 21):3772–83.PubMedView ArticleGoogle Scholar
  66. Omasits U, Ahrens CH, Muller S, Wollscheid B. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics. 2014;30(6):884–6.PubMedView ArticleGoogle Scholar
  67. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015;43(Database issue):D512–20.PubMedView ArticleGoogle Scholar
  68. Pullamsetti SS, Berghausen EM, Dabral S, Tretyn A, Butrous E, Savai R, Butrous G, Dahal BK, Brandes RP, Ghofrani HA, et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2012;32(6):1354–65.PubMedView ArticleGoogle Scholar
  69. Abebe W, Agrawal DK. Role of tyrosine kinases in norepinephrine-induced contraction of vascular smooth muscle. J Cardiovasc Pharmacol. 1995;26(1):153–9.PubMedView ArticleGoogle Scholar
  70. Hughes AD, Wijetunge S. Role of tyrosine phosphorylation in excitation-contraction coupling in vascular smooth muscle. Acta Physiol Scand. 1998;164(4):457–69.PubMedView ArticleGoogle Scholar
  71. Weilinger NL, Tang PL, Thompson RJ. Anoxia-induced NMDA receptor activation opens pannexin channels via Src family kinases. J Neurosci. 2012;32(36):12579–88.PubMedView ArticleGoogle Scholar
  72. Iglesias R, Locovei S, Roque A, Alberto AP, Dahl G, Spray DC, Scemes E. P2X7 receptor-Pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol. 2008;295(3):C752–60.PubMedPubMed CentralView ArticleGoogle Scholar
  73. Riquelme MA, Cea LA, Vega JL, Boric MP, Monyer H, Bennett MV, Frank M, Willecke K, Saez JC. The ATP required for potentiation of skeletal muscle contraction is released via pannexin hemichannels. Neuropharmacology. 2013;75:594–603.PubMedView ArticleGoogle Scholar
  74. Poornima V, Vallabhaneni S, Mukhopadhyay M, Bera AK. Nitric oxide inhibits the pannexin 1 channel through a cGMP-PKG dependent pathway. Nitric Oxide. 2015;47:77–84.PubMedView ArticleGoogle Scholar
  75. Lee MR, Li L, Kitazawa T. Cyclic GMP causes Ca2+ desensitization in vascular smooth muscle by activating the myosin light chain phosphatase. J Biol Chem. 1997;272(8):5063–8.PubMedView ArticleGoogle Scholar
  76. Hess DT, Stamler JS. Regulation by S-nitrosylation of protein post-translational modification. J Biol Chem. 2012;287(7):4411–8.PubMedView ArticleGoogle Scholar
  77. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6(2):150–66.PubMedView ArticleGoogle Scholar
  78. Figueroa XF, Lillo MA, Gaete PS, Riquelme MA, Saez JC. Diffusion of nitric oxide across cell membranes of the vascular wall requires specific connexin-based channels. Neuropharmacology. 2013;75:471–8.PubMedView ArticleGoogle Scholar
  79. McKinnon RL, Lidington D, Bolon M, Ouellette Y, Kidder GM, Tyml K. Reduced arteriolar conducted vasoconstriction in septic mouse cremaster muscle is mediated by nNOS-derived NO. Cardiovasc Res. 2006;69(1):236–44.PubMedView ArticleGoogle Scholar
  80. McKinnon RL, Bolon ML, Wang HX, Swarbreck S, Kidder GM, Simon AM, Tyml K. Reduction of electrical coupling between microvascular endothelial cells by NO depends on connexin37. Am J Physiol Heart Circ Physiol. 2009;297(1):H93–101.PubMedPubMed CentralView ArticleGoogle Scholar
  81. Straub AC, Billaud M, Johnstone SR, Best AK, Yemen S, Dwyer ST, Looft-Wilson R, Lysiak JJ, Gaston B, Palmer L, et al. Compartmentalized connexin 43 s-nitrosylation/denitrosylation regulates heterocellular communication in the vessel wall. Arterioscler Thromb Vasc Biol. 2011;31(2):399–407.PubMedView ArticleGoogle Scholar
  82. Munoz MF, Puebla M, Figueroa XF. Control of the neurovascular coupling by nitric oxide-dependent regulation of astrocytic Ca(2+) signaling. Front Cell Neurosci. 2015;9:59.PubMedPubMed CentralView ArticleGoogle Scholar
  83. Kondo RP, Wang SY, John SA, Weiss JN, Goldhaber JI. Metabolic inhibition activates a non-selective current through connexin hemichannels in isolated ventricular myocytes. J Mol Cell Cardiol. 2000;32(10):1859–72.PubMedView ArticleGoogle Scholar
  84. Retamal MA, Cortes CJ, Reuss L, Bennett MV, Saez JC. S-nitrosylation and permeation through connexin 43 hemichannels in astrocytes: induction by oxidant stress and reversal by reducing agents. Proc Natl Acad Sci U S A. 2006;103(12):4475–80.PubMedPubMed CentralView ArticleGoogle Scholar
  85. Zhang L, Deng T, Sun Y, Liu K, Yang Y, Zheng X. Role for nitric oxide in permeability of hippocampal neuronal hemichannels during oxygen glucose deprivation. J Neurosci Res. 2008;86(10):2281–91.PubMedView ArticleGoogle Scholar
  86. Thompson RJ, Zhou N, MacVicar BA. Ischemia opens neuronal gap junction hemichannels. Science. 2006;312(5775):924–7.PubMedView ArticleGoogle Scholar
  87. Prochnow N, Hoffmann S, Dermietzel R, Zoidl G. Replacement of a single cysteine in the fourth transmembrane region of zebrafish pannexin 1 alters hemichannel gating behavior. Exp Brain Res. 2009;199(3-4):255–64.PubMedView ArticleGoogle Scholar
  88. Bunse S, Schmidt M, Prochnow N, Zoidl G, Dermietzel R. Intracellular cysteine 346 is essentially involved in regulating Panx1 channel activity. J Biol Chem. 2010;285(49):38444–52.PubMedPubMed CentralView ArticleGoogle Scholar
  89. Bunse S, Schmidt M, Hoffmann S, Engelhardt K, Zoidl G, Dermietzel R. Single cysteines in the extracellular and transmembrane regions modulate pannexin 1 channel function. J Membr Biol. 2011;244(1):21–33.PubMedView ArticleGoogle Scholar
  90. Lohman AW, Weaver JL, Billaud M, Sandilos JK, Griffiths R, Straub AC, Penuela S, Leitinger N, Laird DW, Bayliss DA, et al. S-nitrosylation inhibits pannexin 1 channel function. J Biol Chem. 2012;287(47):39602–12.PubMedPubMed CentralView ArticleGoogle Scholar
  91. Harnett KM, Biancani P. Calcium-dependent and calcium-independent contractions in smooth muscles. Am J Med. 2003;115(Suppl 3A):24S–30.PubMedView ArticleGoogle Scholar
  92. Moosmang S, Lenhardt P, Haider N, Hofmann F, Wegener JW. Mouse models to study L-type calcium channel function. Pharmacol Ther. 2005;106(3):347–55.PubMedView ArticleGoogle Scholar
  93. Jackson WF. Ion channels and vascular tone. Hypertension. 2000;35(1 Pt 2):173–8.PubMedPubMed CentralView ArticleGoogle Scholar
  94. Kuo L, Chilian WM, Davis MJ. Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. Am J Phys. 1991;261(6 Pt 2):H1706–15.Google Scholar
  95. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53(2):319–56.PubMedGoogle Scholar
  96. Hill MA, Davis MJ, Meininger GA, Potocnik SJ, Murphy TV. Arteriolar myogenic signalling mechanisms: Implications for local vascular function. Clin Hemorheol Microcirc. 2006;34(1-2):67–79.PubMedGoogle Scholar
  97. Murphy TV, Spurrell BE, Hill MA. Cellular signalling in arteriolar myogenic constriction: involvement of tyrosine phosphorylation pathways. Clin Exp Pharmacol Physiol. 2002;29(7):612–9.PubMedView ArticleGoogle Scholar
  98. Earley S, Resta TC, Walker BR. Disruption of smooth muscle gap junctions attenuates myogenic vasoconstriction of mesenteric resistance arteries. Am J Physiol Heart Circ Physiol. 2004;287(6):H2677–86.PubMedView ArticleGoogle Scholar
  99. Lagaud G, Karicheti V, Knot HJ, Christ GJ, Laher I. Inhibitors of gap junctions attenuate myogenic tone in cerebral arteries. Am J Physiol Heart Circ Physiol. 2002;283(6):H2177–86.PubMedView ArticleGoogle Scholar
  100. Young EJ, Hill MA, Wiehler WB, Triggle CR, Reid JJ. Reduced EDHF responses and connexin activity in mesenteric arteries from the insulin-resistant obese Zucker rat. Diabetologia. 2008;51(5):872–81.PubMedView ArticleGoogle Scholar
  101. Braet K, Aspeslagh S, Vandamme W, Willecke K, Martin PE, Evans WH, Leybaert L. Pharmacological sensitivity of ATP release triggered by photoliberation of inositol-1,4,5-trisphosphate and zero extracellular calcium in brain endothelial cells. J Cell Physiol. 2003;197(2):205–13.PubMedView ArticleGoogle Scholar
  102. Eltzschig HK, Eckle T, Mager A, Kuper N, Karcher C, Weissmuller T, Boengler K, Schulz R, Robson SC, Colgan SP. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ Res. 2006;99(10):1100–8.PubMedView ArticleGoogle Scholar
  103. Evans WH, De Vuyst E, Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J. 2006;397(1):1–14.PubMedPubMed CentralView ArticleGoogle Scholar
  104. Bao L, Sachs F, Dahl G. Connexins are mechanosensitive. Am J Physiol Cell Physiol. 2004;287(5):C1389–95.PubMedView ArticleGoogle Scholar
  105. Piao H, Sato A, Nozawa Y, Sun W, Morioka T, Oite T. Effects of connexin-mimetic peptides on perfusion pressure in response to phenylephrine in isolated, perfused rat kidneys. Clin Exp Nephrol. 2011;15(2):203–11.PubMedView ArticleGoogle Scholar
  106. Esseltine JL, Laird DW. Next-Generation Connexin and Pannexin Cell Biology. Trends Cell Biol. 2016.Google Scholar
  107. Billaud M, Sandilos JK, Isakson BE. Pannexin 1 in the regulation of vascular tone. Trends Cardiovasc Med. 2012;22(3):68–72.PubMedPubMed CentralView ArticleGoogle Scholar
  108. Angus JA, Wright CE. Novel alpha1-adrenoceptor antagonism by the fluroquinolone antibiotic trovafloxacin. Eur J Pharmacol. 2016;791:179–84.PubMedView ArticleGoogle Scholar
  109. Kauffenstein G, Tamareille S, Prunier F, Roy C, Ayer A, Toutain B, Billaud M, Isakson BE, Grimaud L, Loufrani L, et al. Central Role of P2Y6 UDP Receptor in Arteriolar Myogenic Tone. Arterioscler Thromb Vasc Biol. 2016;36(8):1598–606.PubMedView ArticleGoogle Scholar
  110. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol. 2006(176 Pt 1):213-254.Google Scholar
  111. Cherian PP, Siller-Jackson AJ, Gu S, Wang X, Bonewald LF, Sprague E, Jiang JX. Mechanical strain opens connexin 43 hemichannels in osteocytes: a novel mechanism for the release of prostaglandin. Mol Biol Cell. 2005;16(7):3100–6.PubMedPubMed CentralView ArticleGoogle Scholar
  112. Buvinic S, Poblete MI, Donoso MV, Delpiano AM, Briones R, Miranda R, Huidobro-Toro JP. P2Y1 and P2Y2 receptor distribution varies along the human placental vascular tree: role of nucleotides in vascular tone regulation. J Physiol. 2006;573(Pt 2):427–43.PubMedPubMed CentralView ArticleGoogle Scholar
  113. Duza T, Sarelius IH. Conducted dilations initiated by purines in arterioles are endothelium dependent and require endothelial Ca2+. Am J Physiol Heart Circ Physiol. 2003;285(1):H26–37.PubMedView ArticleGoogle Scholar
  114. Winter P, Dora KA. Spreading dilatation to luminal perfusion of ATP and UTP in rat isolated small mesenteric arteries. J Physiol. 2007;582(Pt 1):335–47.PubMedPubMed CentralView ArticleGoogle Scholar
  115. Godecke S, Roderigo C, Rose CR, Rauch BH, Godecke A, Schrader J. Thrombin-induced ATP release from human umbilical vein endothelial cells. Am J Physiol Cell Physiol. 2012;302(6):C915–23.PubMedView ArticleGoogle Scholar
  116. Gomes P, Srinivas SP, Van Driessche W, Vereecke J, Himpens B. ATP release through connexin hemichannels in corneal endothelial cells. Invest Ophthalmol Vis Sci. 2005;46(4):1208–18.PubMedView ArticleGoogle Scholar
  117. Gomes P, Srinivas SP, Vereecke J, Himpens B. ATP-dependent paracrine intercellular communication in cultured bovine corneal endothelial cells. Invest Ophthalmol Vis Sci. 2005;46(1):104–13.PubMedView ArticleGoogle Scholar
  118. Gaynullina D, Shestopalov VI, Panchin Y, Tarasova OS. Pannexin 1 facilitates arterial relaxation via an endothelium-derived hyperpolarization mechanism. FEBS Lett. 2015;589(10):1164–70.PubMedView ArticleGoogle Scholar
  119. Chadjichristos CE, Derouette JP, Kwak BR. Connexins in atherosclerosis. Adv Cardiol. 2006;42:255–67.PubMedView ArticleGoogle Scholar
  120. Looft-Wilson RC, Billaud M, Johnstone SR, Straub AC, Isakson BE. Interaction between nitric oxide signaling and gap junctions: effects on vascular function. Biochim Biophys Acta. 2012;1818(8):1895–902.PubMedView ArticleGoogle Scholar
  121. Takeuchi H, Suzumura A. Gap junctions and hemichannels composed of connexins: potential therapeutic targets for neurodegenerative diseases. Front Cell Neurosci. 2014;8:189.PubMedPubMed CentralView ArticleGoogle Scholar
  122. Bennett MV, Garre JM, Orellana JA, Bukauskas FF, Nedergaard M, Saez JC. Connexin and pannexin hemichannels in inflammatory responses of glia and neurons. Brain Res. 2012;1487:3–15.PubMedPubMed CentralView ArticleGoogle Scholar
  123. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER, Armstrong AJ, Penuela S, Laird DW, Salvesen GS, et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature. 2010;467(7317):863–7.PubMedPubMed CentralView ArticleGoogle Scholar
  124. Kanneganti TD, Lamkanfi M, Kim YG, Chen G, Park JH, Franchi L, Vandenabeele P, Nunez G. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity. 2007;26(4):433–43.PubMedView ArticleGoogle Scholar
  125. Adamson SE, Leitinger N. The role of pannexin1 in the induction and resolution of inflammation. FEBS Lett. 2014;588(8):1416–22.PubMedPubMed CentralView ArticleGoogle Scholar
  126. Kerr NM, Johnson CS, Zhang J, Eady EK, Green CR, Danesh-Meyer HV. High pressure-induced retinal ischaemia reperfusion causes upregulation of gap junction protein connexin43 prior to retinal ganglion cell loss. Exp Neurol. 2012;234(1):144–52.PubMedView ArticleGoogle Scholar
  127. Danesh-Meyer HV, Kerr NM, Zhang J, Eady EK, O'Carroll SJ, Nicholson LF, Johnson CS, Green CR. Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following retinal ischaemia. Brain. 2012;135(Pt 2):506–20.PubMedView ArticleGoogle Scholar
  128. Wei R, Wang J, Xu Y, Yin B, He F, Du Y, Peng G, Luo B. Probenecid protects against cerebral ischemia/reperfusion injury by inhibiting lysosomal and inflammatory damage in rats. Neuroscience. 2015;301:168–77.PubMedView ArticleGoogle Scholar
  129. Thuringer D, Berthenet K, Cronier L, Jego G, Solary E, Garrido C. Oncogenic extracellular HSP70 disrupts the gap-junctional coupling between capillary cells. Oncotarget. 2015;6(12):10267–83.PubMedPubMed CentralView ArticleGoogle Scholar
  130. Huckstepp RT, id Bihi R, Eason R, Spyer KM, Dicke N, Willecke K, Marina N, Gourine AV, Dale N. Connexin hemichannel-mediated CO2-dependent release of ATP in the medulla oblongata contributes to central respiratory chemosensitivity. J Physiol. 2010;588(Pt 20):3901–20.PubMedPubMed CentralView ArticleGoogle Scholar
  131. Robertson J, Lang S, Lambert PA, Martin PE. Peptidoglycan derived from Staphylococcus epidermidis induces Connexin43 hemichannel activity with consequences on the innate immune response in endothelial cells. Biochem J. 2010;432(1):133–43.PubMedView ArticleGoogle Scholar
  132. Ponsaerts R, D'Hondt C, Hertens F, Parys JB, Leybaert L, Vereecke J, Himpens B, Bultynck G. RhoA GTPase switch controls Cx43-hemichannel activity through the contractile system. PLoS One. 2012;7(7):e42074.PubMedPubMed CentralView ArticleGoogle Scholar
  133. Calder BW, Matthew Rhett J, Bainbridge H, Fann SA, Gourdie RG, Yost MJ. Inhibition of connexin 43 hemichannel-mediated ATP release attenuates early inflammation during the foreign body response. Tissue Eng Part A. 2015;21(11-12):1752–62.PubMedPubMed CentralView ArticleGoogle Scholar
  134. Voskresensky IV, Wise ES, Hocking KM, Li FD, Osgood MJ, Komalavilas P, Brophy C, Cheung-Flynn J. Brilliant blue FCF as an alternative dye for saphenous vein graft marking: effect on conduit function. JAMA Surg. 2014;149(11):1176–81.PubMedPubMed CentralView ArticleGoogle Scholar
  135. Hernandez-Salinas R, Vielma AZ, Arismendi MN, Boric MP, Saez JC, Velarde V. Boldine prevents renal alterations in diabetic rats. J Diabetes Res. 2013;2013:593672.PubMedPubMed CentralView ArticleGoogle Scholar
  136. Ellsworth ML, Forrester T, Ellis CG, Dietrich HH. The erythrocyte as a regulator of vascular tone. Am J Physiol Heart Circ Physiol. 1995;269(6):H2155–61.Google Scholar
  137. Gonzalez-Alonso J, Olsen DB, Saltin B. Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery: role of circulating ATP. Circ Res. 2002;91(11):1046–55.PubMedView ArticleGoogle Scholar
  138. Bergfeld GR, Forrester T. Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res. 1992;26(1):40–7.PubMedView ArticleGoogle Scholar
  139. Ellsworth ML. Red blood cell-derived ATP as a regulator of skeletal muscle perfusion. In: Med Sci Sports Exerc. vol. 36. United States; 2004: 35-41.Google Scholar
  140. Sprague RS, Ellsworth ML. Erythrocyte-derived ATP and perfusion distribution: role of intracellular and intercellular communication. Microcirculation. 2012;19(5):430–9.PubMedPubMed CentralView ArticleGoogle Scholar
  141. Dietrich HH, Ellsworth ML, Sprague RS, Dacey Jr RG. Red blood cell regulation of microvascular tone through adenosine triphosphate. Am J Physiol Heart Circ Physiol. 2000;278(4):H1294–8.PubMedGoogle Scholar
  142. Qiu F, Wang J, Spray DC, Scemes E, Dahl G. Two non-vesicular ATP release pathways in the mouse erythrocyte membrane. FEBS Lett. 2011;585(21):3430–5.PubMedPubMed CentralView ArticleGoogle Scholar
  143. Locovei S, Bao L, Dahl G. Pannexin 1 in erythrocytes: function without a gap. Proc Natl Acad Sci U S A. 2006;103(20):7655–9.PubMedPubMed CentralView ArticleGoogle Scholar
  144. Sridharan M, Adderley SP, Bowles EA, Egan TM, Stephenson AH, Ellsworth ML, Sprague RS. Pannexin 1 is the conduit for low oxygen tension-induced ATP release from human erythrocytes. Am J Physiol Heart Circ Physiol. 2010;299(4):H1146–52.PubMedPubMed CentralView ArticleGoogle Scholar
  145. Sridharan M, Sprague RS, Adderley SP, Bowles EA, Ellsworth ML, Stephenson AH. Diamide decreases deformability of rabbit erythrocytes and attenuates low oxygen tension-induced ATP release. Exp Biol Med (Maywood). 2010;235(9):1142–8.View ArticleGoogle Scholar
  146. Olearczyk JJ, Stephenson AH, Lonigro AJ, Sprague RS. NO inhibits signal transduction pathway for ATP release from erythrocytes via its action on heterotrimeric G protein Gi. Am J Physiol Heart Circ Physiol. 2004;287(2):H748–54.PubMedView ArticleGoogle Scholar
  147. Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci. 2004;117(Pt 16):3415–25.PubMedView ArticleGoogle Scholar
  148. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.PubMedView ArticleGoogle Scholar
  149. Angelillo-Scherrer A, Fontana P, Burnier L, Roth I, Sugamele R, Brisset A, Morel S, Nolli S, Sutter E, Chassot A, et al. Connexin 37 limits thrombus propensity by downregulating platelet reactivity. Circulation. 2011;124(8):930–9.PubMedView ArticleGoogle Scholar
  150. Vaiyapuri S, Jones CI, Sasikumar P, Moraes LA, Munger SJ, Wright JR, Ali MS, Sage T, Kaiser WJ, Tucker KL, et al. Gap junctions and connexin hemichannels underpin hemostasis and thrombosis. Circulation. 2012;125(20):2479–91.PubMedPubMed CentralView ArticleGoogle Scholar
  151. Vaiyapuri S, Moraes LA, Sage T, Ali MS, Lewis KR, Mahaut-Smith MP, Oviedo-Orta E, Simon AM, Gibbins JM. Connexin40 regulates platelet function. Nat Commun. 2013;4:2564.PubMedPubMed CentralView ArticleGoogle Scholar
  152. Molica F, Morel S, Meens MJ, Denis JF, Bradfield PF, Penuela S, Zufferey A, Monyer H, Imhof BA, Chanson M, et al. Functional role of a polymorphism in the Pannexin1 gene in collagen-induced platelet aggregation. In: Thromb Haemost, vol. 114. 2015.Google Scholar
  153. Taylor KA, Wright JR, Vial C, Evans RJ, Mahaut-Smith MP. Amplification of human platelet activation by surface pannexin-1 channels. J Thromb Haemost. 2014;12(6):987–98.PubMedPubMed CentralView ArticleGoogle Scholar
  154. Fung C, Cendana C, Farndale R, Mahaut-Smith M. Primary and secondary agonists can use P2X1 receptors as a major pathway to increase intracellular Ca2+ in the human platelet. J Thromb Haemost. 2007;5:910–7.PubMedPubMed CentralView ArticleGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement